Pharsight

Latuda patents expiration

LATUDA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(1 year, 3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Feb, 2024

(10 days ago)

US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia
Feb, 2024

(10 days ago)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Aug, 2024

(5 months from now)

USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound
Dec, 2025

(1 year, 9 months from now)

US8883794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US9555027 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US9907794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US8729085 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US9907794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US8883794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US8729085

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(7 years from now)

US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(7 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders
Nov, 2031

(7 years from now)

Latuda is owned by Sunovion Pharms Inc.

Latuda contains Lurasidone Hydrochloride.

Latuda has a total of 15 drug patents out of which 2 drug patents have expired.

Expired drug patents of Latuda are:

  • US9174975
  • US9815827

Latuda was authorised for market use on 28 October, 2010.

Latuda is available in tablet;oral dosage forms.

Latuda can be used as treatment of schizophrenia with improvement in attention function in schizophrenia; treatment of bipolar depression with improvement in attention function in bipolar disorder, treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder, treatment of schizophrenia, treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia, treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia.

The generics of Latuda are possible to be released after 23 November, 2031.

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2010

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of ...

Dosage: TABLET;ORAL

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents